Management

Image of Rachel K. King

Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI).  Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms.  Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation.  Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. through the company’s early stage, initial public offering, and eventual sale to Novartis.  After the sale to Novartis, she was named CEO and ran the company as a wholly owned subsidiary of Novartis. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston.  She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.  Mrs. King is the past Chair of the full Board of the Biotechnology Innovation Organization (“BIO”) and of BIO’s Emerging Companies Governing Board and continues to serve on BIO’s Executive Committee.  She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley, and now serves on the board of directors of Warp Drive Bio, a Third Rock Ventures-funded biotechnology company based in Cambridge, and of the University of Maryland BioPark.

Image of John Magnani, Ph.D.

Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Prior to co-founding GMI, Dr. Magnani founded and led the predecessor company, GlycoTech Corporation as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, (NIADDK) of the National Institutes of Health (NIH). He remained at the NIH for ten years, finally serving as a tenured Research Chemist. Dr. Magnani is an expert in glycobiology having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9, and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lea and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology and has authored over 100 scientific publications and is an inventor on over 30 issued patents. 

Image of Helen Thackray, M.D., FAAP

Dr. Thackray joined GlycoMimetics in 2006. She has extensive experience in design and execution of pediatric and adult clinical development programs, including early-stage development of novel biologics and small molecules through to successful demonstration of clinical efficacy. In addition, she has a particular interest in Orphan Drug and accelerated regulatory path programs such as Fast Track and Breakthrough Therapy.  At GlycoMimetics, she oversees development of investigational products for the company, including clinical programs in sickle cell disease (now in Phase 3 at Pfizer, Inc.), AML (a Breakthrough Therapy program), multiple myeloma, other cancers and thrombosis, and supportive manufacturing and preclinical work. Concurrent to her position at GlycoMimetics, Dr. Thackray holds an appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine and is a board-certified hospital-based pediatrician. Previously, she was Vice President of Clinical Product Development at Biosynexus, Inc. While at Biosynexus, Dr. Thackray oversaw the complex clinical development of a biologic product in hospitalized neonates. Prior to entering industry, she completed a pediatrics residency at Children's National Medical Center in Washington, D.C., followed by a year as Pediatric Chief Resident and Adjunct Instructor in Pediatrics. She served as a Medical Genetics Fellow at the National Human Genome Research Institute of the National Institutes of Health. Dr. Thackray received her B.S. from Stanford University and her M.D. from George Washington University School of Medicine. She has served as a member of the Institutional Review Board of the National Center for Healthcare Statistics; served on the BIO PDUFA V Technical Discussions team; and is a Fellow of the American Academy of Pediatrics.

Image of Brian Hahn

Mr. Hahn has over 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly traded specialty pharmaceutical company. Prior to Advancis, he was a senior accountant with Bering Truck Corporation. He began his career as an auditor for the Bank of Clarke County. Over the last ten years, Mr. Hahn has worked with life science companies from early stages through product launch. He has been involved in multiple initial public offerings and has broad experience in developing strategic plans, creating business models, establishing accounting and auditing systems, and ensuring Sarbanes-Oxley compliance. Currently, Mr. Hahn serves as Co-Chairman of the BIO Finance and Tax Committee and as a Co-Chairman of the Steering Committee of the DC chapter of the Association for Bio Financial Officers (ABFO), and also serves on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies. He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

Image of Armand Girard

Mr. Girard has extensive partnering experience having completed collaborations, licenses, acquisitions and spinouts by and between leading pharmaceutical and biotech companies. As the GlycoMimetics Vice President of Corporate Development, he is responsible for corporate strategy, for pursuing partnering and licensing opportunities in support of the GlycoMimetics pipeline, and for managing the company's corporate and institutional alliances. Prior to joining GlycoMimetics, he held the position of Vice President for Technical Assessment at Shire Pharmaceuticals, and has more than 20 years of business development, research and development and project management experience. Prior to serving as Vice President for Technical Assessment, Mr. Girard served as a Senior Director for Business Development at Shire. He has held various roles in the biotechnology industry over the past 20 years for companies such as Strakan Life Sciences, Pro-Virus, Inc. and Otsuka Pharmaceuticals. Mr. Girard holds an M.B.A. from St. Joseph's University Haub School of Business, and a B.A. from Lehigh University.

Image of Henry Flanner

Mr. Flanner has over 20 years of experience in the development of biopharmaceutical products in emerging pharmaceutical companies. He joined GlycoMimetics in 2007 bringing knowledge and experience in chemistry, manufacturing and controls (CMC) as well as biopharmaceutics.  At GlycoMimetics, he oversees the scale-up and optimization of manufacturing processes for production of clinical supplies for all phases of development. He also manages the non-clinical toxicology and pharmacokinetics programs for the company. Prior to joining GlycoMimetics, Mr. Flanner was Senior Director of Pharmaceutical Research at MiddleBrook Pharmaceuticals, and previously served as Director of Drug Delivery Sciences at Shire Laboratories.  He holds over 20 formulation patents and co-developed the in vitro dissolution profile comparison factors, f1 and f2, cited in multiple regulatory guidances.  He received a B.S. in Chemical Engineering from the University of South Carolina, and a Master of Chemical Engineering from Johns Hopkins University.